Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo
- 1 March 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 103 (5) , 1966-1967
- https://doi.org/10.1182/blood-2003-10-3475
Abstract
Appel et al[1][1] reported in January that the paradigmatic KIT, PDGFR, ABL tyrosine kinase inhibitor imatinib mesylate (STI571/Gleevec), known to induce potent antitumor effects in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors, acts on nonmalignant hematopoietic cells,Keywords
This publication has 11 references indexed in Scilit:
- Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cellsBlood, 2004
- Inhibitory effect of imatinib on normal progenitor cells in vitroBlood, 2004
- The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemiaHematological Oncology, 2003
- Viable c-KitW/W Mutants Reveal Pivotal Role for c-Kit in the Maintenance of LymphopoiesisImmunity, 2002
- Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu–overexpressing cancersBlood, 2002
- Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapyProceedings of the National Academy of Sciences, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemiaNature Medicine, 2000
- Flt3 ligand induces tumor regression and antitumor immune responses in vivoNature Medicine, 1997
- GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cellsNature, 1992